December 4, 2022

by Will Feuer

– Advertisement –

Pfizer Inc. said it has agreed to supply six million treatment courses of Paxlovid, its oral treatment for COVID-19, to the Global Fund for Low- and Middle-Income Countries, based on Pfizer’s tiered pricing .

– Advertisement –

The Global Fund says it is a movement focused on defeating HIV, tuberculosis and malaria. According to its website, it raises and invests $4 billion annually to fight the world’s deadliest infectious diseases. The organization’s COVID-19 response mechanism has awarded $4.3 billion to 131 countries since April 2020 to reduce the pandemic’s impact on programs to fight HIV, TB and malaria, its website says.

Pfizer said the Global Fund’s COVID-19 response mechanism has been a key channel for providing grant assistance to low- and middle-income countries to purchase COVID testing, treatment and personal protective equipment. The company said the PaxLovid treatment course will be available for purchase through the program subject to local regulatory approval or authorization of the treatment.

– Advertisement –

Pfizer said it expects supplies to be available from this year, with PaxLovid supplements offered based on the company’s level-headed pricing approach, in which low- and lower-middle-income countries will not pay the price for benefits. . The company did not disclose other financial details of the deal.

Write to Will Feuer at [email protected]

See also  Daily Crunch: Microsoft says vulnerable component in IoT devices creates ‘supply chain risk’